- Regorafenib, sold
under the
brand name
Stivarga among others, is an oral multi-kinase
inhibitor developed by
Bayer which targets angiogenic,
stromal and...
- dyspnea, diarrhea, and pyrexia.
Regorafenib (marketed
under the
trade name
Stivarga), is
currently being studied as a
potential treatment option in multiple...
- "key growth"
products were
Xarelto (rivaroxaban),
Eylea (aflibercept),
Stivarga (regorafenib),
Xofigo (radium-223), and
Adempas (riociguat).: 93 Top-selling...
-
coming for
avapritinib as well (Dr
Sameer Rastogi, et al.)
Regorafenib (
Stivarga) was FDA-approved in 2013 for
advanced GISTs that
cannot be surgically...
-
approved for
liver cancer including: atezolizumab, nivolumab, keytruda,
stivarga, etc. Increasingly,
immunotherapy agents (also
called targeted cancer therapies...
- (PDF). FDA. Food and Drug Administration.
Retrieved 20
September 2018. "
Stivarga (regorafenib) dosing, indications, interactions,
adverse effects, and more"...
